Tracers / [11C]TGN-020

[11C]TGN-020

Also written as [11C]TGN-020; [C-11]TGN-020
Radionuclide
C-11 t½ 20.36 min
Modality
PET
Production route
Stage
Syntheses indexed
1

What it is

Compound class
Aquaporin-4 (AQP4) inhibitor, nicotinic acid-thiadiazole derivative
Target / mechanism
Aquaporin-4 (AQP4) PMID 40186669
Clinical application
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
In-house / custom built
in-house
custom manifoldHPLC2.8 ± 0.7%> 95%3-bromopyridine
Tokyo Chemical Industry, Tokyo, Japan
40186669
2025 EJNMMI Radiopharm Chem
[11C]TGN-020 was synthesized using an automated multi-purpose radiosynthesis apparatus developed in-house (Kawamura et al. 2019). — achieving a high radiochemical yield based on [11C]CO2 (610‒1700 MBq, 2.8 ± 0.7%) at the end of synthesis (n = 12)

Need this precursor?We can point you to suppliers for [11C]TGN-020, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [11C]TGN-020.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with C-11.